References
- Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139–154.
- Hammer-Helmich L, Haro JM, Jonsson B, et al. Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. NDT. 2018;14:239–249.
- IsHak WW, James DM, Mirocha J, et al. Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016;7(3):160–169.
- Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157(2):220–228.
- Barrios M, Gomez-Benito J, Pino O, et al. Functioning in patients with schizophrenia: a multicentre study evaluating the clinical perspective. Psychiatry Res. 2018;270:1092–1098.
- Treatment Advocacy Center. Schizophrenia fact sheet. [cited 2018 Nov 14]. Available from: https://www.treatmentadvocacycenter.org/evidence-and-research/learn-more-about/25-schizophrenia-fact-sheet.
- NIH: Mental health information on bipolar disorder. [cited 2018 Nov 14]. Available from: https://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml.
- DBSA. Bipolar disorder statistics. [cited 2018 Nov 14]. Available from: https://secure2.convio.net/dabsa/site/SPageServer/?pagename=education_statistics_bipolar_disorder.
- Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. PS. 2009;60(2):147–156.
- Brown S, Kim M, Mitchell C, et al. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2):116–121.
- NIH: Mental health information on major depression. [cited 2018 Nov 14]. Available from: https://www.nimh.nih.gov/health/statistics/major-depression.shtml.
- ADAA: Understand the facts: depression. [cited 2018 Nov 14]. Available from: https://adaa.org/understanding-anxiety/depression.
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
- Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry. 2000;02(06):194–204.
- Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord. 2014;169 (Suppl 1):S34–S44.
- Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. AJP. 2009;166(9):980–991.
- Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(S1):29–37.
- Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321–334.
- Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.
- Practice guideline for the treatment of patients with major depressive disorder: Third edition: American Psychiatric Association; 2010. [cited 2018 Nov 14]. Available from: https://www.guidelinecentral.com/summaries/practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition/#section-society.
- Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–351.
- Caroff SN, Mu F, Ayyagari R, et al. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306.
- Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10(1):2.
- Roussidis A, Kalkavoura C, Dimelis D, et al. Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study. Ann Gen Psychiatry. 2013;12(1):42.
- Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;07 (03):121–129.
- Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–136.
- Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand. 1987;75(1):74–77.
- Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol. 2000;20(2):188–194.
- Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (NY). 2014;4:266.
- Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–156.
- Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–148.
- Gilbert PL, Harris M, McAdams L, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52(3):173–188.
- Carroll B, Mu F, Ayyagari R, et al. Hospital utilization rates following antipsychotic dose reductions among patients with bipolar and major depressive disorders; 2017. [cited 2018 Nov 14]. Available from: https://www.psychcongress.com/posters/hospital-utilization-rates-following-antipsychotic-dose-reductions-among-patients-bipolar.
- Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin. 2002;18(4):201–208.
- Grande I, Bernardo M, Bobes J, et al. Antipsychotic switching in bipolar disorders: a systematic review. Int J Neuropsychopharm. 2014;17(03):497–507.
- Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(06):764–771.
- Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness-1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):213–219.
- Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(02):155–162.
- Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm. 2002;59(suppl_8):S22–S26.
- Cortese L, Jog M, McAuley TJ, et al. Assessing and monitoring antipsychotic-induced movement disorders in hospitalized patients: a cautionary study. Can J Psychiatry. 2004;49(1):31–36.
- Kleinbaum D, Klein M. Survival analysis: a self-learning text. 3rd ed. New York (NY): Springer; 2012.